Anti-dystrophin T cell responses in duchenne muscular dystrophy: Prevalence and a glucocorticoid treatment effect

Human Gene Therapy

Volumn 24, Issue 9, 2013, Pages 797-806

  Flanigan, Kevin M ^a   Campbell, Katie ^a   Viollet, Laurence ^a   Wang, Wei ^a   Gomez, Ana Maria ^a   Walker, Christopher M ^a   Mendell, Jerry R ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; DYSTROPHIN; GAMMA INTERFERON; PARVOVIRUS VECTOR; PREDNISONE;

ADENO ASSOCIATED VIRUS; AGE DISTRIBUTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRUG EXPOSURE; DUCHENNE MUSCULAR DYSTROPHY; ENZYME LINKED IMMUNOSPOT ASSAY; EXON; FEMALE; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE MUTATION; HUMAN; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; RISK ASSESSMENT; T LYMPHOCYTE; TRANSGENE; TREATMENT RESPONSE;

AGE FACTORS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DEPENDOVIRUS; DYSTROPHIN; GENETIC THERAPY; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCULAR DYSTROPHY, DUCHENNE; PREDNISONE; PREGNENEDIONES;

EID: 84883713705     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.092     Document Type: Article

References (23)

1. Arahata, K., and Engel, A.G. (1984). Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol. 16, 193-208.
2. Arechavala-Gomeza, V., Kinali, M., Feng, L., et al. (2010). Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials. Neuromuscul. Disord. 20, 295-301.
3. Courdier-Fruh, I., Barman, L., Briguet, A., and Meier, T. (2002). Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers. Neuromuscul. Disord. 12(Suppl. 1), S95-S104.
4. Engel, A.G., and Biesecker, G. (1982). Complement activation in muscle fiber necrosis: Demonstration of the membrane attack complex of complement in necrotic fibers. Ann. Neurol. 12, 289-296.
5. Fanin, M., Danieli, G.A., Vitiello, L., et al. (1992). Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients. Neuromuscul. Disord. 2, 41-45.
6. Fanin, M., Danieli, G.A., Cadaldini, M., et al. (1995). Dystrophinpositive fibers in Duchenne dystrophy: Origin and correlation to clinical course. Muscle Nerve 18, 1115-1120.
7. Jacobs, S.C., Bootsma, A.L., Willems, P.W., et al. (1996). Prednisone can protect against exercise-induced muscle damage. J. Neurol. 243, 410-416.
8. Kissel, J.T., Burrow, K.L., Rammohan, K.W., and Mendell, J.R.; CIDD Study Group. (1991). Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 41, 667-672.
9. Klein, C.J., Coovert, D.D., Bulman, D.E., et al. (1992). Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): Evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am. J. Hum. Genet. 50, 950-959.
10. Luzzani, F., Barone, D., Galliani, G., and Glasser, A. (1983). Ex vivo binding to glucocorticoid receptors in the thymus of the adrenalectomized rat. Eur. J. Pharmacol. 87, 61-66.
11. Makedonas, G., Hutnick, N., Haney, D., et al. (2010). Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog. 6, e1000798.
12. Malik, V., Rodino-Klapac, L.R., Viollet, L., et al. (2010). Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol. 67, 771-780.
13. Manzur, A.Y., Kuntzer, T., Pike, M., and Swan, A. (2008). Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 1, CD003725.
14. Mendell, J.R., Campbell, K., Rodino-Klapac, L., et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363, 1429-1437.
15. Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., et al. (2013). Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. (in press)
16. Omote, M., Sakai, K., and Mizusawa, H. (1994). Acute effects of deflazacort and its metabolite 21-desacetyl-deflazacort on allergic reactions. Arzneimittelforschung 44, 149-153.
17. Scudeletti, M., Piccardo, C., Piovano, P., et al. (1987). Effects of a new heterocyclic glucocorticoid, deflazacort (DFC), on the functions of lymphocytes from patients with rheumatoid arthritis (RA). Int. J. Immunopharmacol. 9, 133-139.
18. Seder, R.A., Darrah, P.A., and Roederer, M. (2008). T-cell quality in memory and protection: Implications for vaccine design. Nat. Rev. Immunol. 8, 247-258.
19. Spencer, M.J., Montecino-Rodriguez, E., Dorshkind, K., and Tidball, J.G. (2001). Helper (CD4+ ) and cytotoxic (CD8+) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol. 98, 235-243.
20. Thanh, L.T., Nguyen, T.M., Helliwell, T.R., and Morris, G.E. (1995). Characterization of revertant muscle fibers in Duchenne muscular dystrophy, using exon-specific monoclonal antibodies against dystrophin. Am. J. Hum. Genet. 56, 725-731.
21. Uchino, M., Tokunaga, M., Mita, S., et al. (1995). PCR and immunocytochemical analyses of dystrophin-positive fibers in Duchenne muscular dystrophy. J. Neurol. Sci. 129, 44-50.
22. Winnard, A.V., Mendell, J.R., Prior, T.W., et al. (1995). Frameshift deletions of exons 3-7 and revertant fibers in Duchenne muscular dystrophy: Mechanisms of dystrophin production. Am. J. Hum. Genet. 56, 158-166.
23. Zhang, N., and Bevan, M.J. (2011). CD8+ T cells: Foot soldiers of the immune system. Immunity 35, 161-168.